Highlights
Loss of GPRC5D, whether present at diagnosis or acquired during treatment, emerges as a critical driver of multiple myeloma aggressiveness. Monoallelic loss reduces target antigen expression, enabling escape from GPRC5D-directed immunotherapies. More strikingly, complete biallelic loss reprograms cellular machinery toward enhanced proliferation, creating a pro-growth environment that may be paradoxically selected for during treatment. These findings carry significant implications for patient monitoring and the development of next-generation therapeutic strategies.
Background: The Promise and Challenge of GPRC5D-Directed Therapies
Multiple myeloma remains an incurable hematologic malignancy characterized by the clonal proliferation of plasma cells in the bone marrow. Despite advances in proteasome inhibition, immunomodulatory drugs, and autologous transplantation, disease progression and therapeutic resistance continue to limit long-term survival. The advent of immunotherapy has transformed the treatment landscape, with cellular therapies such as chimeric antigen receptor (CAR) T cells and bispecific antibodies achieving remarkable response rates in heavily pretreated patients.
GPRC5D (G protein-coupled receptor, class C, group 5, member D) has emerged as a promising surface antigen for immunotherapy development. Its restricted expression pattern—predominantly on plasma cells and certain hairy cell populations—makes it an attractive target for selective tumor elimination. However, emerging clinical evidence has revealed a concerning pattern: GPRC5D alterations, including monoallelic loss at baseline and biallelic loss following therapy exposure, occur with increasing frequency in treated patients.
The functional consequences of these genetic alterations have remained largely unexplored, creating a critical knowledge gap that impedes optimal therapeutic utilization. Understanding whether and how GPRC5D loss affects tumor biology and treatment responsiveness is essential for developing strategies to overcome or prevent this resistance mechanism.
Study Design: Modeling Genetic Alterations in Multiple Myeloma
To systematically investigate the impact of GPRC5D alterations, researchers employed the OPM-2 multiple myeloma cell line as their experimental model. This cell line was chosen for its known GPRC5D expression characteristics and suitability for genetic manipulation. The study design involved generating isogenic models representing three distinct genetic states: wild-type GPRC5D (preserving normal two-allele expression), monoallelic loss (simulating baseline alterations observed in newly diagnosed patients), and biallelic loss (mimicking complete inactivation either present at diagnosis or acquired following targeted therapy).
The investigators conducted comprehensive phenotypic and functional characterization across these models. Surface GPRC5D expression was quantified using flow cytometry. Responsiveness to GPRC5D-directed immunotherapies was assessed through cytotoxic assays. Transcriptomic profiling was performed using RNA sequencing to identify gene expression changes associated with complete GPRC5D loss. Phosphoproteomic analysis illuminated signaling pathway alterations. Proliferation assays and competitive fitness experiments determined the functional consequences of each genetic state.
This approach enabled direct comparison of cellular behavior across the spectrum of GPRC5D alterations, providing mechanistic insight into how each genetic change affects tumor cell biology and therapeutic vulnerability.
Key Findings
Monoallelic Loss Confers Resistance to GPRC5D-Directed Therapies
The first critical finding demonstrated that monoallelic loss of GPRC5D significantly reduces cell surface expression of the target antigen. Flow cytometry analysis revealed substantially decreased GPRC5D protein levels on the cell surface of monoallelic loss models compared to wild-type controls. This reduction in target density directly translated to diminished efficacy of GPRC5D-directed immunotherapies, as demonstrated by reduced cytotoxicity in functional assays.
This observation holds significant clinical relevance, as monoallelic GPRC5D loss occurs frequently in newly diagnosed patients. Such patients may exhibit inherently reduced sensitivity to GPRC5D-directed approaches, suggesting that baseline genetic testing for GPRC5D alterations could inform patient selection and treatment sequencing decisions.
Biallelic Loss Promotes a Pro-Proliferative Cellular State
Perhaps the most striking finding concerns the consequences of complete biallelic GPRC5D loss. Rather than simply conferring a passive survival advantage through antigen loss, complete GPRC5D inactivation actively transforms the cellular phenotype toward enhanced aggressiveness. RNA sequencing revealed substantial transcriptional reprogramming in biallelic loss cells, with altered expression of genes involved in cell cycle regulation, metabolic pathways, and cellular communication.
The phosphoproteomic analysis uncovered widespread changes in cellular signaling architecture. Complete GPRC5D loss was associated with altered phosphorylation patterns across multiple kinase pathways, indicating fundamental shifts in how these cells sense and respond to environmental signals. Notably, these changes were not merely adaptive responses but appeared to drive the acquisition of a distinctly pro-proliferative phenotype.
The investigators identified a pro-proliferative chemokine environment as a hallmark of GPRC5D-deficient cells. Secreted factors from these cells promoted enhanced growth rates both in vitro and in competitive co-culture conditions. The basal proliferation rate of cells with complete GPRC5D loss was significantly elevated compared to wild-type counterparts, indicating that this genetic alteration confers a intrinsic growth advantage independent of therapeutic selection pressure.
Competitive Fitness Advantage Under Treatment Selection
Perhaps most concerning from a clinical perspective, the enhanced proliferative capacity of GPRC5D-deficient cells translates to a substantial competitive advantage during ongoing treatment. In co-culture experiments simulating the tumor microenvironment during active therapy, GPRC5D-deficient cells demonstrated superior replicative fitness and progressively outcompeted wild-type cells.
This finding suggests a concerning dynamic: while anti-GPRC5D immunotherapy effectively eliminates tumor cells expressing the target antigen, any pre-existing or emergent GPRC5D-deficient clones would be simultaneously selected for by the same treatment pressure. The therapeutic intervention may therefore inadvertently promote the emergence of a more aggressive tumor population—a paradoxical outcome that could explain observations of aggressive relapse in some patients receiving GPRC5D-directed therapies.
Expert Commentary and Clinical Implications
These findings illuminate a previously unrecognized therapeutic paradox in multiple myeloma management. GPRC5D-directed immunotherapies represent a major advance for patients who have exhausted conventional treatment options. However, the present study demonstrates that the very mechanism of these therapies—targeting a surface antigen—creates selective pressure for tumor evolution toward antigen loss, which is itself associated with enhanced aggressiveness.
Several clinical implications emerge from these observations. First, baseline assessment of GPRC5D genetic status may warrant incorporation into treatment planning algorithms. Patients with pre-existing monoallelic loss might benefit from alternative therapeutic approaches or combination strategies that do not rely exclusively on GPRC5D targeting. Second, the emergence of GPRC5D alterations during treatment monitoring could serve as an early warning sign of impending treatment failure and disease acceleration.
Third, the identification of downstream signaling changes in GPRC5D-deficient cells opens potential therapeutic vulnerabilities. The pro-proliferative chemokine environment and altered phosphoproteomic circuitry represent candidate pathways that could be exploited to prevent or overcome resistance. Rational combination approaches that simultaneously target GPRC5D and these compensatory pathways merit investigation.
The study also raises important questions about optimal treatment sequencing. Given that GPRC5D-deficient clones may have a competitive advantage regardless of treatment, understanding the factors that influence the rate of alteration acquisition and clonal selection becomes paramount. Longitudinal genomic monitoring during GPRC5D-directed therapy could provide valuable data to guide treatment decisions.
Conclusion
This study fundamentally advances our understanding of tumor evolution during targeted immunotherapy for multiple myeloma. By demonstrating that GPRC5D loss represents not merely a resistance mechanism but an active driver of disease aggressiveness, the findings carry profound implications for clinical practice and drug development. The competitive fitness advantage conferred by GPRC5D deficiency creates a scenario where treatment success against antigen-expressing clones may be undermined by the parallel emergence of more proliferative, antigen-deficient populations.
Future research should focus on developing strategies to prevent or delay the emergence of GPRC5D-deficient clones, potentially through rational combination approaches that address the compensatory signaling pathways activated by antigen loss. Clinical monitoring protocols should incorporate serial assessment of GPRC5D status to enable early intervention when alterations emerge. Finally, the development of next-generation constructs that can recognize alternative antigens or engage immune mechanisms independent of GPRC5D density may help overcome the limitations identified in this study.
As the therapeutic arsenal for multiple myeloma continues to expand, understanding the complex interplay between treatment pressure and tumor evolution will be essential for translating molecular discoveries into durable clinical benefit. The GPRC5D story exemplifies both the remarkable promise and the nuanced challenges inherent in precision oncology approaches to this incurable disease.
Funding
This study was supported by multiple research grants as detailed in the original publication. The investigators acknowledge the contribution of funding agencies in enabling this research.
References
Munawar U, Thurner J, Nerreter S, et al. Loss of GPRC5D enhances the proliferative capacity and competitive fitness of myeloma upon anti-GPRC5D immunotherapy. Leukemia. 2026. PMID: 41917280.